摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

O-pivaloyl-L-phenyllactic acid | 105852-83-3

中文名称
——
中文别名
——
英文名称
O-pivaloyl-L-phenyllactic acid
英文别名
(S)-3-phenyl-2-(pivaloyloxy)propanoic acid;(2S)-2-(2,2-dimethylpropionyl)oxy-3-phenylpropionic acid;3-phenyl-2(S)-pivaloyloxypropionic acid;(2S)-2-(2,2-dimethylpropanoyloxy)-3-phenylpropanoic acid
O-pivaloyl-L-phenyllactic acid化学式
CAS
105852-83-3
化学式
C14H18O4
mdl
——
分子量
250.295
InChiKey
YCSAEJLWLWMFFL-NSHDSACASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    18
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    63.6
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2S,4S,5S)-5-[(S)-2-Amino-3-(1H-imidazol-4-yl)-propionylamino]-6-cyclohexyl-4-hydroxy-2-isopropyl-hexanoic acid butylamide 、 O-pivaloyl-L-phenyllactic acid1-羟基苯并三唑N,N'-二环己基碳二亚胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 [(2S)-1-[[(2S)-1-[[(2S,3S,5S)-5-(butylcarbamoyl)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl] 2,2-dimethylpropanoate
    参考文献:
    名称:
    Synthesis and biological activity of some transition-state inhibitors of human renin
    摘要:
    A series of renin inhibitors containing the dipeptide transition state mimics (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-7-methyloctanoic acid (Leu (OH)/Val) and (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-6-cyclohexylhexanoic acid (CHa /(OH)/Val) was prepared. A structure-activity study with Boc-Phe-His-Leu (OH)/Val-Ile-His-NH2 (8a) as starting material led to N-[(2S)-2-[(tert-butylsulfonyl)methyl]-3-phenylpropionyl]-His-Cha (OH)/ Val- NHC4H9-n (8i) which has the length of a tetrapeptide and contains only one natural amino acid. Compound 8i had an IC50 of 2 x 10(-9) M against human renin and showed high enzyme specificity; IC50 values against the related aspartic proteinases pepsin and cathepsin D were (8 x 10(-6) and 3 x 10(-6) M, respectively). In salt-depleted marmosets, 8i inhibited plasma renin activity PRA and lowered blood pressure for up to 2 h after oral administration of a dose of 10 mg/kg.
    DOI:
    10.1021/jm00117a027
  • 作为产物:
    描述:
    L-(-)-3-苯基乳酸 在 palladium on activated charcoal N,N-二乙基吡啶-4-胺氢气N,N-二异丙基乙胺 作用下, 以 甲醇二氯甲烷 为溶剂, 反应 1.0h, 生成 O-pivaloyl-L-phenyllactic acid
    参考文献:
    名称:
    Synthesis and biological activity of some transition-state inhibitors of human renin
    摘要:
    A series of renin inhibitors containing the dipeptide transition state mimics (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-7-methyloctanoic acid (Leu (OH)/Val) and (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-6-cyclohexylhexanoic acid (CHa /(OH)/Val) was prepared. A structure-activity study with Boc-Phe-His-Leu (OH)/Val-Ile-His-NH2 (8a) as starting material led to N-[(2S)-2-[(tert-butylsulfonyl)methyl]-3-phenylpropionyl]-His-Cha (OH)/ Val- NHC4H9-n (8i) which has the length of a tetrapeptide and contains only one natural amino acid. Compound 8i had an IC50 of 2 x 10(-9) M against human renin and showed high enzyme specificity; IC50 values against the related aspartic proteinases pepsin and cathepsin D were (8 x 10(-6) and 3 x 10(-6) M, respectively). In salt-depleted marmosets, 8i inhibited plasma renin activity PRA and lowered blood pressure for up to 2 h after oral administration of a dose of 10 mg/kg.
    DOI:
    10.1021/jm00117a027
点击查看最新优质反应信息

文献信息

  • Novel amino acid derivatives possessing renin-inhibitory activities
    申请人:Japan Tobacco Inc.
    公开号:EP0396065A1
    公开(公告)日:1990-11-07
    An amino acid derivative of the general formula: wherein R1 is wherein, R10 is a lower alkyl group and R" is (wherein R111 is a lower alkyl group and n is an integer of 1 to 5) or a lower alkyl group which may be substituted by hydroxy group or methoxyethoxymethoxy group, or R'° and R" are combinedly together with the adjacent nitrogen atom; R12 is a hydrogen atom, CnH2n+1-O-CO- (n is as defined above) or R'3 is a lower alkyl group which may be substituted by substituent(s) selected from HOOC-(H2C)n-O-, R12- NH- (n and R12 are as defined above) and pyridyl group; X is -CH2-, -O- or -NH- and Y is -O- or -NH-; wherein (wherein Z is -0-, -S-, -S(O)-. -S(O)2-, -CH2-, -CH(OH)-, or and a and b are independently an integer of 1 to 4 and the total of a and b is not more than 5) ; R2 is an aralkyl group which may be substituted by lower alkyl group(s); R3 is a hydrogen atom or a lower alkyl group; R4 is a lower alkyl group; and A is hydroxy group and B is a hydrogen atom, or A and B are carbonyl group combinedly together with the adjacent carbon atom, a pharmaceutically acceptable acid addition salt or an ester thereof is described. The compounds of the invention possess inhibitory activities against renin and are useful as an antihypertensive agent.
    通用公式的氨基酸衍生物: 其中R1为 其中,R10为较低的烷基基团,R"为 (其中R111为较低的烷基基团,n为1至5的整数)或者可以被羟基或甲氧乙氧甲氧基取代的较低烷基基团,或者R'°和R"与相邻的氮原子 结合在一起; R12为氢原子,CnH2n+1-O-CO-(n如上定义)或者 R'3为可以被HOOC-(H2C)n-O-、R12-NH-(n和R12如上定义)和吡啶基取代的较低烷基基团; X为-CH2-、-O-或-NH-,Y为-O-或-NH-;其中 (其中Z为-0-、-S-、-S(O)-、-S(O)2-、-CH2-、-CH(OH)-, 或 a和b分别独立为1至4的整数,且a和b的总和不超过5); R2为可以被较低烷基基团取代的芳基烷基基团; R3为氢原子或较低烷基基团; R4为较低烷基基团; A为羟基,B为氢原子,或者A和B与相邻的碳原子结合在一起,描述了一种药学上可接受的酸盐或其酯。本发明的化合物具有对肾素的抑制活性,并可用作降压药。
  • Access to benzene-modified 2<sup>nd</sup> generation strigolactams and GR24 by merging C–H olefination with decarboxylative Giese cyclization
    作者:Yuhua Ge、Xingyue Chen、Yi Dong、Hua-Nan Wang、Yangyan Li、Gang Chen
    DOI:10.1039/d1ob01234g
    日期:——

    Herein, we reported an efficient and general synthetic route to assemble benzene-modified 2nd generation strigolactams and GR24. The key features of this synthesis include a palladium-catalyzed ortho-selective olefination and a decarboxylative Giese radical cyclization.

    在这里,我们报告了一种高效且通用的合成路线,用于组装苯改性的第二代异槲聚糖和GR24。这种合成的关键特点包括钯催化的正向选择性烯烃化和脱羧Giese自由基环化。
  • Novel 5-amino-4-hydroxyvaleryl derivatives
    申请人:Ciba-Geigy Corporation
    公开号:US04727060A1
    公开(公告)日:1988-02-23
    Compounds of the formula ##STR1## in which R.sub.1 represents hydrogen or acyl, A represents an optionally N-alkylated .alpha.-amino acid residue which is bonded N-terminally to R.sub.1 and C-terminally to the group --NR.sub.2 --, R.sub.2 represents hydrogen or lower alkyl, R.sub.3 represents hydrogen, lower alkyl, optionally etherified or esterified hydroxy-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, tricycloalkyl-lower alkyl, aryl or aryl-lower alkyl, R.sub.4 represents hydroxy or etherified or esterified hydroxy, R.sub.5 represents lower alkyl having 2 or more carbon atoms, optionally etherified or esterified hydroxy-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl, bicycloalkyl-lower alkyl, tricycloalkyl, tricycloalkyl-lower alkyl, aryl, aryl-lower alkyl, optionally substituted carbamoyl, optionally substituted amino, optionally substituted hydroxy or optionally substituted mercapto and R.sub.6 represents substituted amino, and salts of such compounds having salt-forming groups inhibit the blood pressure-increasing action of the enzyme renin and can be used as antihypertensives.
    式为##STR1##的化合物,其中R.sub.1代表氢或酰基,A代表一个可选的N-烷基化的α-氨基酸残基,其N-末端与R.sub.1和C-末端与--NR.sub.2--基团连接,R.sub.2代表氢或较低的烷基,R.sub.3代表氢、较低烷基、可选地醚化或酯化的羟基较低烷基、环烷基、环烷基较低烷基、双环烷基较低烷基、三环烷基较低烷基、芳基或芳基较低烷基,R.sub.4代表羟基或醚化或酯化的羟基,R.sub.5代表具有2个或更多碳原子的较低烷基、可选地醚化或酯化的羟基较低烷基、环烷基、环烷基较低烷基、双环烷基、双环烷基较低烷基、三环烷基、三环烷基较低烷基、芳基、芳基较低烷基、可选地取代的氨基甲酰基、可选地取代的氨基、可选地取代的羟基或可选地取代的巯基,R.sub.6代表取代的氨基,以及具有形成盐的基团的这类化合物的盐,抑制肾素酶增加血压的作用,可用作降压药。
  • 5-Amino-4-hydroxyvalerylamid-Derivate
    申请人:CIBA-GEIGY AG
    公开号:EP0184550A2
    公开(公告)日:1986-06-11
    Verbindungen der Formel worin R, Wasserstoff oder Acyl, A einen gegebenenfalls N-alkylierten α-Ammosäurerest, der N-terminal mit R, und C-terminal mit der Gruppe -NR2- verbunden ist, R2 Wasserstoff oder Niederalkyl, R3 Wasserstoff, Niederalkyl, gegebenenfalls veräthertes oder verestertes Hydroxyniederalkyl, Cycloalkyl, Cycloalkylniederalkyl, Bicycloalkylniederalkyl, Tricycloalkylniederalkyl, Aryl oder Arylniederalkyl, R4 Hydroxy, veräthertes oder verestertes Hydroxy, R5 Niederalkyl mit 2 und mehr C-Atomen, gegebenenfalls veräthertes oder verestertes Hydroxyniederalkyl, Cycloalkyl, Cycloalkylniederalkyl, Bicycloalkyl, Bicycloalkylniederalkyl, Tricycloalkyl, Tricycloalkylniederalkyl, Aryl, Arylniederalkyl, gegebenenfalls substituiertes Carbamoyl, gegebenenfalls substituiertes Amino, gegebenenfalls substituiertes Hydroxy oder gegebenenfalls substituiertes Mercapto und R6substituiertes Amino darstellen, und Salze von solchen Verbindungen mit salzbildenden Gruppen hemmen die blutdrucksteigernde Wirkung des Enzyms Renin und können als Antihypertensiva verwendet werden.
    式中的化合物 其中 R 是氢或酰基,A 是任选 N-烷基化的α-氨基酸残基,其 N 端与 R 相连,C 端与基团 -NR2- 相连,R2 是氢或低级烷基,R3 是氢、低级烷基、任选醚化或酯化的羟基低级烷基、环烷基、环烷基低级烷基、双环烷基低级烷基、三环烷基低级烷基、芳基或芳基低级烷基、环烷基、环烷基-低级烷基、双环烷基-低级烷基、三环烷基-低级烷基、芳基或芳基-低级烷基,R4 羟基、醚化或酯化羟基,R5 具有 2 个或 2 个以上碳原子的低级烷基,可选择醚化或酯化羟基-低级烷基、环烷基、环烷基-低级烷基、双环烷基、双环烷基-低级烷基、三环烷基、三环烷基-低级烷基、芳基、芳基-低级烷基、任选取代的氨基甲酰基、任选取代的氨基、任选取代的羟基或任选取代的巯基和 R6 取代的氨基,以及此类化合物带有成盐基团的盐可抑制肾素酶的升压作用,可用作降压药。
  • BUHLMAYER, PETER;CASELLI, ANTHONY;FUHRER, WALTER;GOSCHKE, RICHARD;RASETTI+, J. MED. CHEM., 31,(1988) N 9, C. 1839-1846
    作者:BUHLMAYER, PETER、CASELLI, ANTHONY、FUHRER, WALTER、GOSCHKE, RICHARD、RASETTI+
    DOI:——
    日期:——
查看更多